Hanlim Pharmaceutical Co., Ltd.

Korea Research Institute of Chemical Technology

Catholic University Industry Academic Cooperation Foundation

Catholic University Academic Cooperation Foundation

Geun-Hyeog Lee

Jin-Ha Park

Mi-La Cho

Hye-Jwa Oh

Mi-Jin O

Eun-Young Kwak

Byong-Sun Choi

Yun-Ju Woo

Jun-Ki Min

Yun-Seok Cho

Sung-Eun Yoo

Choun-Ki Joo

Mi-Jung Kim

Jun-Sub Choi

Kyu-Yang Yi

Jee-Hee Suh

Joo-Yeon Jhun

Eun-Mi Kim

Sang-Yong Lee

Dong-Yeop Shin

Hye-Sung Lee

Hu-Seong Kim

Kyung-Joon Kim

Young-Ok Jung

Se-Wan Park

Jong-Hyeon Ryu

Jae-Sik Yang

Nack-Jeong Kim

Jae-Shin Kim

Jin-Sun Kim

Sung-Il Lee

The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.

Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof

The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Pharmaceutical composition for preventing or treating macular degeneration

The present invention provides a method for preventing or treating osteoarthritis comprising administrating rebamipide or a pharmaceutical composition comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier to a subject in need thereof. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration

The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.

Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide

Growing community of inventors

Gyeonggi-do, South Korea

Geun-Hyeog Lee